NNVC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections...

Stats
Šios dienos apimtis	26 373.00
Vidutinė apimtis	29 345.00
Rinkos kapitalizacija	13.31M
EPS	$0 ( 2024-02-14 )
Kita pelno data	( $-0.190 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.410
ATR14	$0.0300 (2.65%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-08	Diwan Anil	Sell	94 471	Common Stock, par value $0.001 per share
2020-02-07	Jawadakar Makarand	Buy	0
2019-06-02	Day Mark D.	Buy	0
2018-05-21	Boniuk Milton	Buy	5 500 000	Common Stock, par value $0.001 per share
2017-02-21	Boniuk Milton	Buy	1 746 288	Common Stock, par value $0.001 per share

INSIDER POWER
-100.00
Last 95 transactions
Buy: 11 406 507 \| Sell: 1 435 933

NanoViricides Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

NanoViricides Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-747 529 (0.00 %)
EPS:	$-0.740

FY	2023
Pajamos:	$0
Bruto pelnas:	$-747 529 (0.00 %)
EPS:	$-0.740

FY	2022
Pajamos:	$0
Bruto pelnas:	$-723 325 (0.00 %)
EPS:	$-0.700

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

NanoViricides Inc

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.